Invitae Corp (Invitae) is a medical genetics company that provides testing, health data and digital health solutions for various genetic disorders. The company provides genetic testing services in multiple clinical areas that include hereditary cancer, women's health, precision oncology, pharmacogenomics and rare diseases. It uses process automation, proprietary design, robotics and bioinformatics software solutions to support genetic counseling, variant interpretation, and clinical trial matching. The company serves payers, healthcare providers, biopharma partners and patient advocacy groups. It operates in Australia, India, Japan, Singapore, Belgium, Germany, Latvia, the Netherlands, the US, Israel and Brazil. Invitae is headquartered in San Francisco, California, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
The report analyzes all pipeline products in development for the company InVitae Corp
The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
The report provides detailed description of products in development, technical specification and functions
The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
To formulate effective Research & Development strategies
Develop market-entry and market expansion strategies
Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note:Some sections may be missing if data is unavailable for the company
InVitae Corp Company Overview
InVitae Corp Company Snapshot
InVitae Corp Pipeline Products and Ongoing Clinical Trials Overview
InVitae Corp – Pipeline Analysis Overview
InVitae Corp - Key Facts
InVitae Corp - Major Products and Services
InVitae Corp Pipeline Products by Development Stage
Personalized Cancer Monitoring Laboratory Developed Test
Personalized Cancer Monitoring Laboratory Developed Test Product Overview
Therapy selection LDT
Therapy selection LDT Product Overview
InVitae Corp - Key Competitors
InVitae Corp - Key Employees
InVitae Corp - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
InVitae Corp, Recent Developments
Mar 05, 2024: Invitae to Present Data at the 2024 ACMG Annual Clinical Genetics Meeting
Nov 06, 2023: Invitae Launches Enhanced Chemistry of MRD Test to Better Serve Biopharmaceutical Clinical and Research Partnerships
Oct 25, 2023: Landmark Study Reveals Magnitude of Uncertain Results in Clinical Genetic Testing for Hereditary Disease, Points to Evidence-Based Solutions to Reach Definitive Results
Oct 19, 2023: Invitae Appoints Dr. David Sholehvar as Chief Operating Officer
Oct 16, 2023: InVitae Receives DeNovo Clearance for Invitae Common Hereditary Cancers Panel
Oct 12, 2023: Rural Hospital System Demonstrates the Clinical Benefits of Implementing Universal Hereditary Cancer Testing in Patients with Breast Cancer
Sep 29, 2023: FDA Grants First Marketing Authorization for a DNA Test to Assess Predisposition for Dozens of Cancer Types
Sep 25, 2023: Invitae Announces Appointment of Finance Veteran Ana Schrank as CFO
Aug 28, 2023: Invitae Hires Industry Veteran Robert Guigley as Chief Commercial Officer
Aug 15, 2023: Clinical Trial Results Support Genetic Testing Of All Patients With Prostate Cancer